

PR 5

Office of the President
February 19, 2016

Members, Board of Trustees:

APPOINTMENT OF DEAN OF THE COLLEGE OF MEDICINE

Recommendation: that Dr. Robert DiPaola be appointed Dean of the College of Medicine, effective March 31, 2016.

Background: Dr. DiPaola is currently Director of the Rutgers Cancer Institute of New Jersey, Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences, and a tenured Professor of Medicine at Rutgers Robert Wood Johnson Medical School.

Dr. DiPaola earned a B.S. (1984) and medical degree (1988) from the University of Utah. He completed an internship and residency in Internal Medicine at Duke University Medical Center and completed a Fellowship in Hematology-Oncology at the University of Pennsylvania Hospital.

Dr. DiPaola has considerable experience in translational research focused on the study of prostate cancer and drug resistance. He was one of the earliest investigators to target the degradation of bcl-2 and autophagy in both the laboratory and clinic as a means to restore drug sensitivity in prostate cancer; and clinical studies that have had impact on standards of care, including a recent study published in the *New England Journal of Medicine* (2015). His accomplishments in the area of translational research are also underscored by grants from the National Institutes of Health, Department of Defense, American Cancer Society (ACS), and private foundations. His publications have appeared in a number of prominent journals including the *Journal of the American Medical Association*, *Archives of Internal Medicine*, *Cell*, *Genes and Development*, *Clinical Cancer Research*, and the *Journal of Clinical Oncology*.

Dr. DiPaola has maintained continuous federal peer-reviewed funding to support a laboratory focused on Drug Resistance in Cancer Therapy focused on preclinical studies that support translational clinical trials. He is currently the Principal Investigator (PI) of a Cancer Center Support Grant; a Precision Medicine Experimental Therapeutics UM1 Grant; and an ACS grant supporting faculty mentoring, education, and career development. He is currently PI on \$20 million in extramural funding and during his leadership of Rutgers Cancer Institute of New Jersey, their extramural funding increased to greater than \$80 million.

As National Chairman of the Genitourinary Committee of the Eastern Cooperative Oncology Group (2004-2011), he led the committee to develop National phase II and III studies, and through two successful National Cancer Institute (NCI) reviews. He was a full member of

multiple NCI steering committees, including the investigational drug steering committee and the Genitourinary (GU) steering committee, and chairman of an NCI apoptosis and autophagy task force. He was chairman for additional national committees including the program committees of the American Society of Clinical Oncology's GU symposia and the Association of American Cancer Institutes; and is currently a full member of the National Cancer Institute's subcommittee A (parent committee) for Cancer Center reviews.

Action taken: Approved Disapproved Other _____